Explore
Validate
LearnMA1-26529
antibody from Invitrogen Antibodies
Targeting: ABCB1
ABC20, CD243, CLCS, GP170, MDR1, P-gp, PGY1
Western blot
ImmunocytochemistryAntibody data
- Antibody Data
- Antigen structure
- References [12]
- Comments [0]
- Validations
- Western blot [1]
Submit
Validation data
Reference
Comment
Report error
- Product number
- MA1-26529 - Provider product page
- Provider
- Invitrogen Antibodies
- Product name
- Anti-P-Glycoprotein Monoclonal Antibody (C494)
- Antibody type
- Monoclonal
- Antigen
- Recombinant full-length protein
- Description
- MA1-26529 detects P Glycoprotein from human samples. MA1-26529 has been successfully used in immunoprecipitation, immunocytochemistry, immunohistochemistry (paraffin), and Western blot procedures. Positive controls of Drug sensitive parental cell lines and their multidrug-resistant derivatives, human LIver (positive staining detected along luminal surfaces of bile canaliculi) or human colon suggested. A predicted molecular weight of approximately 141 kDa. The MA1-26529 immunogen is recombinant, full length protein. Store at 4ºC short term. For extended storage aliquot and store at -20ºC or below. Avoid freeze/thaw cycles.
- Reactivity
- Human, Mouse, Canine
- Host
- Mouse
- Isotype
- IgG
- Antibody clone number
- C494
- Vial size
- 250 µL
- Concentration
- Lot Dependent
- Storage
- Store at 4°C short term. For long term storage, store at -20°C, avoiding freeze/thaw cycles.
Submitted references Molecular profiling in gastric cancer: examining potential targets for chemotherapy.
Epigenetic regulation of MDR1 gene through post-translational histone modifications in prostate cancer.
Putative supramolecular complexes formed by carotenoids and xanthophylls with ascorbic acid to reverse multidrug resistance in cancer cells.
Differentiated human colorectal cancer cells protect tumor-initiating cells from irinotecan.
Reversal effect of PI3-K inhibitor LY294002 on P-glycoprotein-mediated multidrug resistance of human leukemia cell line K562/DNR and gastric cancer cell line SGC7901/ADR.
Expression of P-glycoprotein and metallothionein in gastrointestinal stromal tumor and leiomyosarcomas. Clinical implications.
Multidrug resistance-related phenotype and apoptosis-related protein expression in ovarian serous carcinomas.
Preoperative localization of parathyroid adenomas with technetium-99m methoxyisobutylisonitrile imaging: relationship with P-glycoprotein expression, oxyphilic cell content, and tumoral tissue volume.
P-glycoprotein expression is induced in human pancreatic cancer xenografts during treatment with a cell cycle regulator, mimosine.
Histopathological features and P-glycoprotein expression in retinoblastoma.
Relationship between histopathological features of chemotherapy treated retinoblastoma and P-glycoprotein expression.
Phase II trial of arsenic trioxide in relapsed and refractory acute myeloid leukemia, secondary leukemia and/or newly diagnosed patients at least 65 years old.
Miura JT, Johnston FM, Thomas J, George B, Eastwood D, Tsai S, Christians KK, Turaga KK, Gamblin TC
Journal of surgical oncology 2014 Sep;110(3):302-6
Journal of surgical oncology 2014 Sep;110(3):302-6
Epigenetic regulation of MDR1 gene through post-translational histone modifications in prostate cancer.
Henrique R, Oliveira AI, Costa VL, Baptista T, Martins AT, Morais A, Oliveira J, Jerónimo C
BMC genomics 2013 Dec 17;14:898
BMC genomics 2013 Dec 17;14:898
Putative supramolecular complexes formed by carotenoids and xanthophylls with ascorbic acid to reverse multidrug resistance in cancer cells.
Molnár J, Serly J, Pusztai R, Vincze I, Molnár P, Horváth G, Deli J, Maoka T, Zalatnai A, Tokuda H, Nishino H
Anticancer research 2012 Feb;32(2):507-17
Anticancer research 2012 Feb;32(2):507-17
Differentiated human colorectal cancer cells protect tumor-initiating cells from irinotecan.
Emmink BL, Van Houdt WJ, Vries RG, Hoogwater FJ, Govaert KM, Verheem A, Nijkamp MW, Steller EJ, Jimenez CR, Clevers H, Borel Rinkes IH, Kranenburg O
Gastroenterology 2011 Jul;141(1):269-78
Gastroenterology 2011 Jul;141(1):269-78
Reversal effect of PI3-K inhibitor LY294002 on P-glycoprotein-mediated multidrug resistance of human leukemia cell line K562/DNR and gastric cancer cell line SGC7901/ADR.
Zhang Y, Qu XJ, Liu YP, Yang XH, Hou KZ, Teng YE, Zhang JD
Ai zheng = Aizheng = Chinese journal of cancer 2009 Feb;28(2):97-9
Ai zheng = Aizheng = Chinese journal of cancer 2009 Feb;28(2):97-9
Expression of P-glycoprotein and metallothionein in gastrointestinal stromal tumor and leiomyosarcomas. Clinical implications.
Pérez-Gutiérrez S, González-Cámpora R, Amérigo-Navarro J, Beato-Moreno A, Sánchez-León M, Pareja Megía JM, Virizuela-Echaburu JA, López-Beltrán A
Pathology oncology research : POR 2007;13(3):203-8
Pathology oncology research : POR 2007;13(3):203-8
Multidrug resistance-related phenotype and apoptosis-related protein expression in ovarian serous carcinomas.
Yakirevich E, Sabo E, Naroditsky I, Sova Y, Lavie O, Resnick MB
Gynecologic oncology 2006 Jan;100(1):152-9
Gynecologic oncology 2006 Jan;100(1):152-9
Preoperative localization of parathyroid adenomas with technetium-99m methoxyisobutylisonitrile imaging: relationship with P-glycoprotein expression, oxyphilic cell content, and tumoral tissue volume.
Turgut B, Elagoz S, Erselcan T, Koyuncu A, Dokmetas HS, Hasbek Z, Ozdemir S, Aydin C
Cancer biotherapy & radiopharmaceuticals 2006 Dec;21(6):579-90
Cancer biotherapy & radiopharmaceuticals 2006 Dec;21(6):579-90
P-glycoprotein expression is induced in human pancreatic cancer xenografts during treatment with a cell cycle regulator, mimosine.
Zalatnai A
Pathology oncology research : POR 2005;11(3):164-9
Pathology oncology research : POR 2005;11(3):164-9
Histopathological features and P-glycoprotein expression in retinoblastoma.
Filho JP, Correa ZM, Odashiro AN, Coutinho AB, Martins MC, Erwenne CM, Burnier MN Jr
Investigative ophthalmology & visual science 2005 Oct;46(10):3478-83
Investigative ophthalmology & visual science 2005 Oct;46(10):3478-83
Relationship between histopathological features of chemotherapy treated retinoblastoma and P-glycoprotein expression.
Souza Filho JP, Martins MC, Caissie AL, Torres VL, Fernandes LH, Erwenne CM, Burnier MN Jr
Clinical & experimental ophthalmology 2005 Jun;33(3):279-84
Clinical & experimental ophthalmology 2005 Jun;33(3):279-84
Phase II trial of arsenic trioxide in relapsed and refractory acute myeloid leukemia, secondary leukemia and/or newly diagnosed patients at least 65 years old.
Parmar S, Rundhaugen LM, Boehlke L, Riley M, Nabhan C, Raji A, Frater JL, Tallman MS
Leukemia research 2004 Sep;28(9):909-19
Leukemia research 2004 Sep;28(9):909-19
No comments: Submit comment
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Western blot was performed using Anti-P-Glycoprotein Monoclonal Antibody (C494) (Product # MA1-26529) and a 260 kDa band due to glycosylation corresponding to ABCB1 was observed across cell lines tested except MCF-7 which is reported to negative. Whole cell extracts (30 µg lysate) of Hep G2 (Lane 1), Caco-2 (Lane 2), MDCK (Lane 3), PC-3 (Lane 4), MCF-7 (Lane 5) and tissue extracts of Mouse Brain (Lane 6) and Mouse Kidney (Lane 7) were electrophoresed using NuPAGE™ 4-12% Bis-Tris Protein Gel (Product # NP0322BOX). Resolved proteins were then transferred onto a nitrocellulose membrane (Product # LC2001) by XCell SureLock™ Mini-Cell and XCell II™ Blot Module (Product # EI0002). The blot was probed with the primary antibody (1:1000 dilution) and detected by chemiluminescence with Goat anti-Mouse IgG (H+L) Superclonal™ Recombinant Secondary Antibody, HRP (Product # A28177, 1:4000 dilution) using the iBright FL 1000 (Product # A32752). Chemiluminescent detection was performed using SuperSignal™ West Dura Extended Duration Substrate (Product # 34076).
